Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-25 @ 9:45 PM
Study NCT ID:
NCT01092351
Status:
COMPLETED
Last Update Posted:
2010-03-24
First Post:
2010-03-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014552', 'term': 'Urinary Tract Infections'}], 'ancestors': [{'id': 'D007239', 'term': 'Infections'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D009582', 'term': 'Nitrofurantoin'}], 'ancestors': [{'id': 'D009581', 'term': 'Nitrofurans'}, {'id': 'D009574', 'term': 'Nitro Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D005663', 'term': 'Furans'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 37}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-03', 'completionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2010-03-22', 'studyFirstSubmitDate': '2010-03-15', 'studyFirstSubmitQcDate': '2010-03-22', 'lastUpdatePostDateStruct': {'date': '2010-03-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-03-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluation of bacteriological efficacy', 'timeFrame': 'after 12-42 days', 'description': 'Bacteriological efficacy is assessed by number and type of isolates in a clean-void midstream urine sample.'}], 'secondaryOutcomes': [{'measure': 'Evaluation of clinical efficacy', 'timeFrame': 'after 12-42 days', 'description': 'Clinical efficacy is assessed by the disappearance/improvement of clinical symptoms (dysuria, frequency, urgency, suprapubic pain).'}, {'measure': 'Evaluation of safety and tolerability', 'timeFrame': '1-42 days', 'description': 'Safety and tolerability of the nitrofurantoin formulation is assessed during whole duration of study by monitoring all adverse events'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['urinary tract infection', 'nitrofurantoin'], 'conditions': ['Urinary Tract Infection']}, 'descriptionModule': {'briefSummary': 'The study aims to investigate bacteriological efficacy of a nitrofurantoin formulation given twice daily for seven days in the treatment of adult patients with microbiologically confirmed uncomplicated urinary tract infection.\n\nAdditional study objectives are to evaluate clinical efficacy as well as safety and tolerability of the nitrofurantoin formulation.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* non-pregnant women and men aged above 18 years old\n* presence of ≥ 2 signs or symptoms suggestive of a UTI (dysuria, urinary frequency, urgency, suprapubic pain) with onset 10 days before enrollment\n* asymptomatic patients with available positive urine culture\n* pyuria defined as positive leucocyte esterase (LE) test with any color change after two minutes\n* collection of clean-voided midstream urine sample for culture and susceptibility testing to confirm bacteriuria\n* normal renal function (defined as blood creatinine \\< 1.4 mg/100 ml)\n* able to take oral medication on an outpatient basis\n* written informed consent before enrollment\n\nExclusion Criteria:\n\n* suspicion of complicated UTI (presence of fever above 38°C, flank pain, known urologic structural abnormality) or prostatitis\n* negative urine dipslide results (uropathogen \\< 100000 CFU (colony-forming units)/mL) or presence of nitrofurantoin resistant isolate uropathogens or mixed cultures of more than two isolates\n* symptoms of UTI within the past 4 weeks\n* evidence of predisposing factor to UTI (e.g. calculi, stricture, primary renal disease like polycystic renal diseases and neurogenic bladder)\n* medical history of anaemia, complicated diabetes mellitus, peripheral neuropathy, vitamin B deficiency, renal insufficiency, other significant renal, hepatic or lung diseases\n* medical history of glucose-6-phosphate dehydrogenase deficiency (G6PD)\n* electrolytes disorders\n* pregnant, breast-feeding women or not using medically accepted, effective method of birth control\n* history of nitrofurantoin hypersensitivity\n* use of systemic bacteriological agent within 48 hours before enrollment'}, 'identificationModule': {'nctId': 'NCT01092351', 'briefTitle': 'Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'Mepha Ltd.'}, 'officialTitle': 'Open Label Study on the Bacteriological and Clinical Efficacy and Safety of a Nitrofurantoin Formulation Given Twice Daily (Bid) for Seven Days in Uncomplicated Urinary Tract Infection in Adults', 'orgStudyIdInfo': {'id': 'NIT 001-2006'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Nitrofurantoin', 'description': 'Adult patients with a microbiologically confirmed uncomplicated urinary tract infection', 'interventionNames': ['Drug: Nitrofurantoin']}], 'interventions': [{'name': 'Nitrofurantoin', 'type': 'DRUG', 'otherNames': ['Uvamin retard'], 'description': '100 mg retard capsules to be taken twice daily for seven days', 'armGroupLabels': ['Nitrofurantoin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '14050', 'city': 'Mexico City', 'country': 'Mexico', 'facility': 'Cif Biotec, Medica Sur', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}], 'overallOfficials': [{'name': 'Arturo Mendoza Valdes, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cif Biotec, Medical Sur'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mepha Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Dr. Adrian Frentzel', 'oldOrganization': 'Mepha Ltd.'}}}}